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Dear Editor, 
A frequent scenario concerning predictive in vitro tests in toxicology is that a compound is 
either tested as toxic or non-toxic in vitro and this prediction is then compared to the human in 
vivo situation for validation. The performance of such binary classification tests is assessed by 
established metrics, for example, sensitivity as the proportion of actual toxic compounds that 
were predicted as such; or sensitivity that measures the proportion of compounds that are non-
toxic and were correctly predicted as non-toxic by the in vitro test.  
However, measures of the performance of binary classifications become suboptimal, when 
concentration or dose-dependent analyses are performed and the tests aim at predicting doses 
that cause an increased risk of toxicity in vivo. Recently, Albrecht et al. (2019) addressed this 
challenge and established the Toxicity Separation Index (TSI) and Toxicity Estimation Index 
(TEI) as new performance metrics. Both, TSI and TEI, are calculated based on the projection 
of positive and negative test compounds onto a two-dimensional coordinate system. Here, the 
y-axis indicates the in vivo blood concentration - for example Cmax - that results from a dosing 
schedule of a test compound, usually from therapeutic doses or from accidental overdoses. The 
x-axis represents the lowest concentration that causes a positive in vitro test result, also called 
in vitro alert. If the test differentiates well between toxic and non-toxic compounds, the toxic 
compounds will appear on top of the non-toxic substances in this presentation. The TSI is a 
continuous number that informs how well the test system differentiates between toxic and non-
toxic compounds; a TSI of 1.0 indicates perfect separation, while a TSI of 0.5 represents a 
random result. The second recently introduced performance measure, the Toxicity Estimation 
Index (TEI), informs how well toxic blood concentrations in vivo can be estimated by the in 
vitro test system. The advantage of these new performance measures is that they can be used to 
optimize test systems. For example, the authors showed that the use of an EC10 instead of EC50 
for cytotoxicity analysis in hepatocytes leads to a higher TSI. Moreover, TEI was improved, 
when gene expression was included into the test battery, meaning that the lower alert concen-
tration of both, cytotoxicity and gene expression resulted in a better TEI than using the alert 
concentration of each test individually. Therefore, the TSI and TEI concept allows to modify a 
test and learn whether the modified version performs better than the original one. Of course, 
conclusions drawn from a training set of compounds need to be validated in an independent 
compound set to avoid overfitting.  
Currently, numerous activities are ongoing to predict in vivo toxicity by in vitro tests (Leist 
et al., 2017; Vinken and Hengstler, 2018), particularly in the fields of hepatotoxicity (Godoy et 
al., 2013, 2016; Hammad, 2013; Frey et al., 2014; Jansen et al., 2017), cardiotoxicity (Sampaio 
et al., 2016; Chaudhari et al., 2016a, b), developmental toxicity (Rempel et al., 2015; Krug et 
al., 2013) and neurotoxicity (Sisnaiske et al., 2014; Micheli et al., 2018; Meléndez et al., 2019; 
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Shinde et al., 2015, 2016). The novel performance metrics introduced by Albrecht et al. will 
help to objectify how well in vitro tests predict specific forms of toxicity in vivo.  
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